Pricing and Reimbursement Report - June 2017

23 June 2017

This report focuses on pricing and reimbursement expectations for key drugs in development and analyses of important events and trends based on BPI’s discussions with key opinion leaders.

Included in this report:

Investigative News
  • ATMP therapies need novel cost-effectiveness models to satisfy payers and investors - expert
  • EU adaptive MAPPS pilot development pathway has credibility to speed up rare and niche approvals, stakeholder trust the major first hurdle – experts
  • Loxo’s larotrectinib and other Trk inhibitor’s uptake pathway may be throttled by mutation- screening hurdles – experts
  • Adaptimmune NY-ESO1 TCR faces sarcoma market challenges due to HLA restrictions – experts
  • AbbVie could reverse UK NICE rejection on Venclyxto with Phase III CLL data expected mid-2017 – experts
  • Jazz’s Vyxeos likely to pass payer approval for on-label sAML, broader use still possible with speedbumps – experts
  • CAR-T pursuits in China face pricing headache for broad coverage, likely restriction to urban regions – experts
  • Global Larotrectinib Sales Forecasts From 2017 - 2027
  • Global Venclyxto Sales Forecasts From 2017 - 2024
  • US Vyxeos Sales Forecasts From 2017 - 2025
  • Proposed US legislation to increase AD opioid access via step removals, lower formulary tiers potentially stunted by patient cost implications – experts
  • Alkermes’ Vivitrol will see increased uptake for opioid addiction with legislation to combat epidemic - experts
  • Legislation to force payer coverage of abuse-deterrent opioids faces resistance due to cost barriers; limited data to support benefit– experts
  • Global Vivitrol Sales Forecasts From 2017 - 2024
  • Amgen’s Repatha’s price its ultimate obstacle to US market penetration despite positive LDL-C outcomes data, expected label change impact unclear – experts
  • Global Repatha Sales Forecasts From 2017 - 2027
  • Sanofi’s Soliqua may struggle to secure European reimbursement acceptance in T2D due to dubious adherence advantages, pricing concerns – experts
  • Global Soliqua Sales Forecasts From 2017 - 2022
  • Alexion’s Strensiq for HPP, Kanuma for LAL-D still faces French reimbursement pushback with price-volume agreements, tough ASMR reach - experts
  • Global Strensiq Sales Forecasts From 2017 - 2027